Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE2 | O96020 | 3/20 | 0.37 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.37 |
| ▸ | CDK2 | P24941 | 3/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.33 |
| ▸ | PDE5A | O76074 | 1/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | GHSR | Q92847 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1591527 | 0.86 | JAK2 (0.37) | CCNE2CCNE1CDK2PTGS2PDE5A | |
| SCHEMBL4438464 | 0.73 | JAK2 (0.34) | CCNE2CCNE1CDK2KDM1APTGS2 | |
| SCHEMBL1591733 | 0.72 | FLT3 (0.40) | PTGS2 | |
| SCHEMBL4436776 | 0.70 | JAK2 (0.35) | CCNE2CCNE1CDK2KDM1APTGS2 | |
| SCHEMBL17815584 | 0.69 | ADORA2A (0.39) | CDK2 | |
| SCHEMBL3584532 | 0.67 | JAK2 (0.45) | CCNE1CDK2PDE5A | |
| SCHEMBL12703912 | 0.64 | JAK2 (0.45) | CCNE1CDK2PDE5A | |
| SCHEMBL17144115 | 0.60 | PDE5A (0.44) | KDM1APTGS2PDE5A | |
| SCHEMBL3586487 | 0.59 | ABL1 (0.39) | PTGS2PDE5A | |
| SCHEMBL12982676 | 0.59 | CDK1 (0.57) | CCNE2CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050124637-A1 | Compounds and compositions as inhibitors of receptor tyrosine kinase activity | IRM LLC (BM) | 2005-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124637-A1 | Compounds and compositions as inhibitors of receptor tyrosine kinase activity | BMX, LCK, FYN | CCNE2 4226/4885CCNE1 2761/4885CDK2 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.